Overview
Location
United States
Total raised
$330M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 24, 2026 | Ollin Biosciences Raises $330M in Series B Funding | Ollin Biosciences, Inc., an Austin, TX-based clinical-stage biotech advancing therapies for vision-threatening diseases, raised $330M in Series B funding. The round was co-led by new investor TCGX and ARCH Venture Partners, with participati... |
| Mar 31, 2026 | Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema | OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN... |
| Jan 9, 2026 | Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration | SAN FRANCISCO and SUZHOU, China, Jan. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| Sep 18, 2025 | Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines fo... |
| Ollin Biosciences | “Accelerating Next Generation Therapies for Ophthalmology” |